FDA Accepts Resubmission of Supplemental Biologics License Application for Dupixent for Chronic Spontaneous Urticaria in Patients Under 12

Medicine

FDA Accepts Resubmission of Supplemental Biologics License Application for Dupixent for Chronic Spontaneous Urticaria in Patients Under 12

November 16, 2024November 16, 2024 admin

The resubmission for Dupixent includes new data in pediatric patients with chronic spontaneous urticaria.

Share

Leave a Reply Cancel reply